H.U. Group Holdings Inc., together with its wholly owned subsidiary Fujirebio, has announced the availability of the Lumipulse G pTau 217 CSF assay designed for use on the fully automated LUMIPULSE G immunoassay analyzers. The new assay uses chemiluminescent enzyme immunoassay technology and is offered for Research Use Only. It enables the quantitative measurement of tau protein phosphorylated at threonine 217 in human cerebrospinal fluid, delivering results in approximately 35 minutes.
Health Technology Insights: AHN Offers Innovative Low-Dose Radiation Therapy for Osteoarthritis
With the addition of the pTau 217 CSF assay, Fujirebio continues to expand its neurological testing portfolio, giving clinical researchers another advanced tool to study neurodegenerative diseases. The assay is intended to support research into Alzheimer’s disease by helping scientists better understand biomarker changes that occur early in the disease process and that may help distinguish Alzheimer’s disease from other forms of dementia.
Health Technology Insights: NeuraLight Unveils Scientific Leaders Advancing Neurology
Alzheimer’s disease is marked by the buildup of abnormal tau proteins that form neurofibrillary tangles, along with amyloid plaques made up of beta amyloid peptides in the brain. Recent research has shown that pTau 217 in cerebrospinal fluid is a promising early indicator of the neuropathological changes associated with Alzheimer’s disease, often appearing before clear clinical symptoms develop.
This latest assay strengthens Fujirebio’s growing range of neurological biomarkers and highlights the company’s ongoing commitment to supporting research and diagnostic development in neurodegenerative diseases. By expanding access to reliable and automated biomarker testing, Fujirebio aims to help advance scientific understanding of complex brain disorders.
Commenting on the launch, Goki Ishikawa, President and Chief Executive Officer of Fujirebio Holdings Inc., explained that the inclusion of pTau 217 CSF in the company’s neuro portfolio allows researchers to explore its value in identifying Alzheimer’s disease at an earlier stage and in differentiating it from non Alzheimer’s dementias. He noted that the CSF assay complements Fujirebio’s existing biomarker offerings, including pTau 217 plasma and other cerebrospinal fluid markers, by supporting earlier and more confident detection of Alzheimer’s related pathology and enabling researchers to address specific scientific questions using a single analytical platform.
The availability of this assay on the fully automated, random access LUMIPULSE G analyzers gives researchers a convenient and reliable way to measure pTau 217 in cerebrospinal fluid, alongside blood based testing. These analyzers are already in routine use worldwide for neurological disease testing and are designed to meet demanding requirements for quality, throughput, and regulatory standards.
Health Technology Insights: Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
